Immunohistochemistry and Biomarkers in Breast Pathology

The track on "Immunohistochemistry and Biomarkers in Breast Pathology" focuses on the critical role of immunohistochemistry (IHC) and biomarkers in the diagnosis, prognosis, and treatment of breast pathology. This track explores the latest advancements in IHC techniques, including the identification and evaluation of key biomarkers such as hormone receptors (ER, PR), HER2/neu, Ki-67, and other emerging markers. Discussions will revolve around their clinical significance, interpretation challenges, and their impact on therapeutic decision-making. Additionally, this track will delve into novel biomarkers and their potential for risk assessment, predicting treatment response, and guiding personalized treatment strategies. Attendees will gain insights into the evolving landscape of IHC and biomarkers, enhancing their understanding of breast pathology evaluation and patient management.

  • Biomarkers for Breast Cancer Subtyping
  • Emerging Biomarkers in Breast Pathology
  • Immunohistochemistry Techniques and Interpretation
  • Role of Immunohistochemistry in Differential Diagnosis
  • Predictive and Prognostic Biomarkers

Related Conference of Immunohistochemistry and Biomarkers in Breast Pathology

June 10-11, 2024

8th Global Meeting on Oncology and Radiology

Barcelona, Spain
July 11-12, 2024

24th World Congress on Cancer and Diagnostics

Vancouver, Canada
July 18-19, 2024

14th World Congress on Breast Cancer

Paris, France
September 16-17, 2024

9th World Conference on Breast and Cervical Cancer

London, UK
September 19-20, 2024

25th World Congress on Cancer Summit

Paris, France
November 24-25, 2024

7th International Conference on Anti-Cancer Drugs

Vancouver, Canada

Immunohistochemistry and Biomarkers in Breast Pathology Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in